Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

cyclooxygenase/vēzis

Saite tiek saglabāta starpliktuvē
Lappuse 1 no 46 rezultātiem

Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to methods for inhibiting cyclooxygenase-2 (COX-2) and tumor necrosis factor alpha (TNF.alpha.) activities and treating disorders and diseases associated with elevated COX-2 and TNF.alpha. activities. 2. Description

Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors. 2. State of

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION This invention is in the field of the prevention and treatment of neoplasia. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. BACKGROUND OF THE INVENTION Prostaglandins play a major

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION This invention is in the field of the prevention and treatment of neoplasia. More specifically, this invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. BACKGROUND OF THE INVENTION Prostaglandins play a major
In recent years, focus is very much on cancer prevention, in acknowledgement of the fact that surgery mostly does not suffice as the only modality and that most cytotoxic regimens are ineffective against solid tumours. With the choices and results of treatment known today, only effective prevention

Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The present invention relates in general to cancer. More specifically, the invention provides methods of predicting disease outcome in gastric cancer patients based on the methylation status of the Cox-2 gene promoter region. SEQUENCE LISTING The present invention contains

Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The present invention relates in general to cancer. More specifically, the invention provides methods of predicting disease outcome in gastric cancer patients based on the methylation status of the Cox-2 gene promoter region. SEQUENCE LISTING The present invention contains

Screening assays for cancer chemopreventative agents

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL AREA OF THE INVENTION The invention relates to the area of cancer chemopreventative agents. More particularly, the invention relates to the area of screening assays for cancer chemopreventative agents. BACKGROUND OF THE INVENTION Because common epithelial cancers have resisted most

Treating cancers associated with overexpression of HER-2/neu

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD This invention is directed to treatment of HER-2/neu overexpressing cancers. BACKGROUND OF THE INVENTION The HER-2/neu (erbB-2) gene product is a 185-kDA transmembrane receptor tyrosine kinase that belongs to the family of receptors for epidermal growth factor. It is described in

Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor ("COX-2 inhibitor") and (b) a histone deacetylase Inhibitor ("HDAI") for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer

Medicinal compositions for treating colorectal cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD The invention relates to a pharmaceutical composition to be administered to the large intestine for treating a colorectal cancer. BACKGROUND ART In cancer therapy the surgical treatment is the mainstream at present. However, in order to improve the performance of the surgical

Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions

Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions

Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD The presently disclosed subject matter relates to methods and compositions for inhibiting a biological activity of a human aldo-keto reductase family 1, member C3 (AKR1C3; also known as type 5 17.beta.-hydroxysteroid dehydrogenase) polypeptide. In some embodiments, the compositions

1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION The invention relates generally to anti-inflammatory drugs, and more particularly to novel compounds which inhibit the activity of cyclooxygenase-2. BACKGROUND OF THE INVENTION The metabolites of arachidonic acid, such as prostaglandins, lipoxygenases and thromboxane products
Pievienojieties mūsu
facebook lapai

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

  • Darbojas 55 valodās
  • Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
  • Garšaugu atpazīšana pēc attēla
  • Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
  • Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
  • Meklēt ārstniecības augus pēc to iedarbības
  • Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem

Google Play badgeApp Store badge